REM Behavior Disorder

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program
1
TasimelteonPhase 11 trial
Active Trials
NCT05922995Terminated20Est. Dec 2023
Takeda
TakedaTOKYO, Japan
1 program
RozeremN/A1 trial
Active Trials
NCT00745030Terminated3Est. Dec 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vanda PharmaceuticalsTasimelteon
TakedaRozerem

Clinical Trials (2)

Total enrollment: 23 patients across 2 trials

NCT05922995Vanda PharmaceuticalsTasimelteon

The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)

Start: Sep 2023Est. completion: Dec 202320 patients
Phase 1Terminated
NCT00745030TakedaRozerem

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

Start: Jun 2008Est. completion: Dec 20093 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space